Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
A phase 2 trial of Tucatinib, Trastuzumab and Fulvestrant in endometrial cancer, cervical cancer, biliary tract cancer and non-small-cell lung cancer, run by Seagen, a wholly owned subsidiary of Pfizer, active and no longer recruiting.
Overview
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations is a phase 2 interventional study registered as NCT04579380 by Seagen, a wholly owned subsidiary of Pfizer, with 217 participants enrolled, started 2021-01-11 and due to reach its primary completion in 2023-11-01. Interventions recorded: tucatinib, trastuzumab and fulvestrant. Results have been posted on the registry.
Similar pages
not linked directly; found by shared links- TrialDose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Shares Biliary tract cancer (cholangiocarcinoma), Endometrial cancer, Cervical cancer and the tag pipeline.
- TrialTucatinib+Trastuzumab+Eribulin in HER2+ MBC
Shares Tucatinib, Trastuzumab and the tag pipeline.
- TrialA Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)
Shares Tucatinib, Trastuzumab and the tag pipeline.
- TrialA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
Shares Biliary tract cancer (cholangiocarcinoma), Endometrial cancer, Non-small-cell lung cancer and the tag pipeline.
- TrialClinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
Shares Tucatinib, Fulvestrant and the tag pipeline.
- Trial177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Shares Endometrial cancer, Cervical cancer, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Shares Tucatinib, Trastuzumab and the tag pipeline.
- TrialStudy of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Shares Tucatinib, Trastuzumab and the tag pipeline.